News & Press
October 23, 2019
Article > Market View: Parenteral Drugs
By Patricia Van Arnum – DCAT® Editorial Director
CordenPharma Roundtable Contribution by
Fabio Stevanon, Global Injectables Platform, CordenPharma International
DCAT Value Chain Insights, October 23, 2019
Parenteral drugs, which may be a biologic or small molecule, refer to drugs using non-oral means of administration by injecting the drug directly into the body typically through three common routes of administration: intramuscular, subcutaneous and intravenous. The percentage of parenteral drugs approved as new molecular entities (NMEs) by the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) (see Table I at end of article) reached a recent high of 59% in 2016 and has since trended near 40% over the past several years.
To gain a perspective of the key trends in development and manufacturing of parenteral drugs, DCAT Value Chain Insights gained input from industry members. Providing perspectives were Claus Feussner, PhD, Senior Vice President Development Service, Vetter Pharma-Fertigung GmbH & Co. KG, and Fabio Stevanon, Director, Global Injectables Platform, CordenPharma International.
Stevanon (CordenPharma):
Generally, as the regulatory authorities’ scrutiny with regards to injectables / parenterals continues to increase, including ever tighter expectations with respect to facility and microbial controls, so does the burden to demonstrate the production of a safe and sterile product.
With respect to small molecules, while the regulatory process is well defined and stringent, there are incentives to developing biologics because these often target unmet medical needs or orphan diseases. In these cases, the regulatory pathway can be shortened, resulting in a more attractive development landscape for innovators to explore.
Stevanon (CordenPharma):
Parenteral drug manufacturing industry-wise, the effort to raise the compliance level of terminally sterilized drugs, which closely mimics the aseptic fill–finish standard, is a clear and evident trend. We also see the movement of aseptic fill–finish facilities toward operating more and more in an “automatic-robotized” environment to improve product protection, as well as operator and environmental protection in the case of highly potent compounds.
With reference to injectable technology, the terminally sterilized manufacturing trend adopts a C-class area close to compound and filling lines while aseptic formulation and filling is forced to adopt open-close restricted-access barrier systems (RABS)(EU GMP_ Annex I driven) or even isolator technology, as well as ready-to-fill technology to limit interaction with materials before the final filling closing step.
With regards to capacity, we have recently seen a significant investment toward high-speed filling lines to address the need for the traditional high-volume marketed drugs. The challenge here is that these high-speed lines are often inflexible with regards to variation or optionality as they are designed to fulfill demands of millions of units per annum.
The other end of the product-volume continuum is represented by the more innovative drugs or niche/orphan product areas, which demand greater flexibility with regard to volumes or components, and, therefore, ultimately require more flexible, slower filling lines. Here capacity and customers’ pricing expectations remain a challenge.
Stevanon (CordenPharma):
Within the injection-delivery scope, the evident increase of subcutaneous over intravenous delivery is driven by patient-centricity and system-friendly technology. In particular, the subcutaneous products are heavily dominated by pre-filled syringes, pens and auto-injectors while wearable devices are becoming more prominent where therapy has to be constantly monitored and data-driven. This is reflected in the implementation of new rules from the US FDA for combination product standards and revised medical device regulations by the European Medicines Agency.
As a consequence, injectable manufacturing is becoming overall less standardized, as seen, for example, in the different interaction between constituents and components, device and combination product testing, control strategy and analytics, and complex packaging diversity, all overseen by cGMP and new drug / device regulations.
Essential cookies are required for basic website functions. This ensures that the website functions properly
The technical storage or access that is used exclusively for statistical purposes.
Name | _ga |
---|---|
Provider | google-analytics.com |
Purpose | This cookie name is associated with Google Universal Analytics - which is a significant update to Google's more commonly used analytics service. This cookie is used to distinguish unique users by assigning a randomly generated number as a client identifier. It is included in each page request in a site and used to calculate visitor, session and campaign data for the sites analytics reports. |
Cookie life cycle | 2 years |
Name | _gid |
---|---|
Provider | google-analytics.com |
Purpose | This cookie is set by Google Analytics. It stores and update a unique value for each page visited and is used to count and track pageviews. |
Cookie life cycle | 1 Day |
Name | collect |
---|---|
Provider | google-analytics.com |
Purpose | "Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels. |
Cookie life cycle | session |
Name | vuid |
---|---|
Provider | vimeo.com |
Purpose | Collects data on the user's visits to the website, such as which pages have been read. These cookies are used by the Vimeo video player on websites. |
Cookie life cycle | 2 years |
Name | BE_CLA3 |
---|---|
Provider | BrightEdge |
Purpose | Enables data aggregation, analysis and report creation to assess marketing effectiveness and for website performance. |
Cookie life cycle | 37199 days |
Name | YSC |
---|---|
Provider | Youtube |
Purpose | This cookie is set by YouTube to track views of embedded videos. |
Cookie life cycle | session |
Name | __utmc |
---|---|
Provider | google-analytics.com |
Purpose | This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour and measure site performance. It is not used in most sites but is set to enable interoperability with the older version of Google Analytics code known as Urchin. In this older versions this was used in combination with the __utmb cookie to identify new sessions/visits for returning visitors. When used by Google Analytics this is always a Session cookie which is destroyed when the user closes their browser. Where it is seen as a Persistent cookie it is therefore likely to be a different technology setting the cookie. |
Cookie life cycle | Session |
Name | __utma |
---|---|
Provider | google-analytics.com |
Purpose | This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour and measure site performance. This cookie lasts for 2 years by default and distinguishes between users and sessions. It it used to calculate new and returning visitor statistics. The cookie is updated every time data is sent to Google Analytics. The lifespan of the cookie can be customised by website owners. |
Cookie life cycle | 2 years |
Name | __utmz |
---|---|
Provider | google-analytics.com |
Purpose | This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour measure of site performance. This cookie identifies the source of traffic to the site - so Google Analytics can tell site owners where visitors came from when arriving on the site. The cookie has a life span of 6 months and is updated every time data is sent to Google Analytics. |
Cookie life cycle | 6 months 2 days |
Name | __utmb |
---|---|
Provider | google-analytics.com |
Purpose | This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour measure of site performance. This cookie identifies the source of traffic to the site - so Google Analytics can tell site owners where visitors came from when arriving on the site. The cookie has a life span of 6 months and is updated every time data is sent to Google Analytics. |
Cookie life cycle | 6 months 2 days |
Name | __utmt |
---|---|
Provider | google-analytics.com |
Purpose | This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour and measure site performance. This cookie determines new sessions and visits and expires after 30 minutes. The cookie is updated every time data is sent to Google Analytics. Any activity by a user within the 30 minute life span will count as a single visit, even if the user leaves and then returns to the site. A return after 30 minutes will count as a new visit, but a returning visitor. |
Cookie life cycle | 30 minutes |
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Name | visitor_id# |
---|---|
Provider | pardot.com |
Purpose | "Used in context with Account-Based-Marketing (ABM). The cookie registers data such as IP-addresses, time spent on the website and page requests for the visit. This is used for retargeting of multiple users rooting from the same IP addresses. ABM usually facilitates B2B marketing purposes." |
Cookie life cycle | 10 years |
Name | visitor_id#-hash |
---|---|
Provider | pardot.com |
Purpose | Used to encrypt and contain visitor data. This is necessary for the security of the user data. |
Cookie life cycle | 10 years |
Name | Google Maps API |
---|---|
Provider | Google Maps |
Purpose | to read user IP address. |
Cookie life cycle | expires immediately |
Name | GPS |
---|---|
Provider | Youtube |
Purpose | YouTube is a Google owned platform for hosting and sharing videos. YouTube collects user data through videos embedded in websites, which is aggregated with profile data from other Google services in order to display targeted advertising to web visitors across a broad range of their own and other websites. |
Cookie life cycle | session |
Name | PREF |
---|---|
Provider | Youtube |
Purpose | This cookie, which may be set by Google or Doubleclick, may be used by advertising partners to build a profile of interests to show relevant ads on other sites. It works by uniquely identifying your browser and device. |
Cookie life cycle | 8 months |
Name | VISITOR_INFO1_LIVE |
---|---|
Provider | Youtube |
Purpose | This cookie is set by Youtube to keep track of user preferences for Youtube videos embedded in sites;it can also determine whether the website visitor is using the new or old version of the Youtube interface. |
Cookie life cycle | 6 months |
#CordenPharmaBoulder #CordenPharmaColorado
Celebrations included a garden party with a festive banquet of foods from Italy, Germany, France, & US, games, marshmallow roasting, custom beer steins and other 15 Year gifts, and balloons stuffed with prizes. All employees then heard a speech from Managing Director Brian McCudden and COO Dr. Lee Newton.
#CordenPharmaBergamo
Celebrations included a garden party with German-themed breakfast, lunch or dinner buffets, 15 Year custom cakes and gifts distributed to all employees, along with a speech from Managing Director Luca Porcu and VP of Platform Management & Marketing Stephen Houldsworth.
#CordenPharmaSwitzerland
Celebrations included an introduction of our core values, followed by playful games to implement them, distribution of 15 year bags, food and a live band in a garden party. Employees heard from Managing Director Dr. Juerg Burger and VP of Human Resources Stefanie Gerber.
#CordenPharmaPlankstadt
Celebrations were split into 3 groups to cover all shifts and included a festive room with a 3 course buffet meal, 15 Year custom gift bags with locally-brewed beer, and a welcome speech by Site Business Development Christina Simons and CEO Dr. Michael Quirmbach.
#CordenPharmaFrankfurt
Celebrations included a garden party with food trucks, table games, a pub quiz with team prizes, instant cameras for a photo collage, and 15 Year gifts. Guests included the CPI Global Compliance Team, Allessa GmbH, Weylchem Innotec GmbH, and Walter Krebs GmbH, with speeches by Head of Operations Dr. Karsten Meyenberg and CFO Heiko Serwe.
#CordenPharmaChenôve
Celebrations included a garden party with a “Burgundy” aperitif dinner, food trucks for lunch, a fun photo booth for taking 15 Year souvenirs, and speeches by Managing Director Yves Michon and CordenPharma Chief Quality & Compliance Officer Will Cashin.
#CordenPharmaCaponago
Celebrations continued 4 times throughout the day & night to cover all shifts, and included a multi-course German lunch or dinner with brezel, speeches by Managing Director Fabrizio Fiordigiglio and VP of Sales Dr. Mimoun Ayoub, followed by a festive garden gazebo for the 15 Year gift distribution of Prosecco and backpacks.
#CordenPharmaBrussels
Celebrations included a boat ride to Brussels City Center, followed by 3 groups taking guided bike or walking tours of secret places along the canal or the Tour & Taxis building. The party finished with a BBQ dinner and speeches from Managing Director Dr. Jean-Luc Dewez and VP General Counsel Nicolas Reischer.
Brittany Hayes joined CordenPharma as Director, Global Highly Potent & Oncology Platform in October 2021, bringing over 20 years of extensive experience in the areas of contract manufacturing (Drug Substance & Drug Product), pharmaceutical and API development, business development, contract management, and organic chemistry.
Prior to joining CordenPharma, Brittany held leadership positions at various Contract Development & Manufacturing Organizations (CDMOs) including Recro, Regis Technologies, DSM/Patheon/Thermo Fisher, Formex, Ricerca, and Azopharma. Most recently, Brittany was Applied Technology Director at Recro, where she was responsible for managing the proposal evaluations and development team, providing technical support to the BD team, creating training for new service offerings, and enhancing new client onboarding & knowledge transfer by liaising with business development executives, technical operations personnel, and project managers. Brittany excels at driving technical decision-making for successful pharmaceutical product development.
Brittany earned her Ph.D. in organic chemistry from Wake Forest University (Winston-Salem, NC) and her B.S. degree in Chemistry from Emory University (Atlanta, GA). She also was an American Heart Association postdoctoral fellow at the University of Illinois at Chicago, Department of Medicinal Chemistry & Pharmacognosy. Brittany has been an active member of the American Chemical Society since 1995.